Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 6, 1997, Pages 531-534

  Kobayashi, Shotai ^a   Tazaki, Yoshiaki ^b  

^a SHIMANE UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Activity of daily living (ADL); Acute cerebral thrombosis; Argatroban; Direct thrombin inhibitor; Double blind controlled study

Indexed keywords

ARGATROBAN; FIBRINOPEPTIDE A;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUSCLE FUNCTION; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

EID: 0031419066     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996131     Document Type: Conference Paper

References (16)

1. Baker RN, JA Broward, HC Fang, CM Fisher, SN Groch, A Heyman, HR Karp, E McDevitt, P Scheinberg, W Schwartz, JF Toole: Anticoagulant therapy in cerebral infarction. Neurology 12:823-835, 1962.
2. Ramirez-Lassepas M, MR Quinones: Heparin therapy for stroke: hemorrhagic complications and risk factors for intracerebral hemorrhage. Neurology 34:114-117, 1984.
3. Shilds RW Jr, R Jaureno, T Lachman, M Victor: Anticoagulant-related hemorrhage in acute cerebral embolism. Stroke 15:426-437, 1984.
4. Bass E: Anticoagulation in cerebral embolism. Can J Neurol Sci 10:32-36, 1983.
5. Millikan CH, FH McDowell: Treatment of progressing stroke. Stroke 12:397-409, 1981.
6. Sampaolo S, J Cervos-Navarro, D Djouchadar, J Figols: Clinical and experimental evidence of microthrombosis in cerebral ischemia. In: Hartmann A, W Kuschinsky (eds): Cerebral Ischemia and Hemorheology. Springer, Berlin-Heidelberg, 1987, pp 386-393.
7. Shinmyozu K, Y Ohkatu, M Osame, A Igata, Y Ohno: Investigation of circulating agglutinated platelets in cerebral vascular diseases. Neurol Med 19:280-282, 1983.
8. Nagayama M, Y Shinohara: Investigation of pathogenesis of thrombus formation in juvenile cerebral infarction - Evaluation with a new marker of the blood coagulation/fibrinolysis system. J Adult Dis 20:556-xxx, 1990.
9. Okamoto S, A Hijikata, R Kikumoto, S Tonomura, H Hara, K Ninomiya, A Maruyama, M Sugano, K Tamao: Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereostructure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 101: 440-446, 1981.
10. 2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)-sulfonyl]-L-arginyl)-2- piperidinecarboxylic acid. Biochemistry 23:85-90, 1984.
11. Hara H, K Tamao, R Kikumoto: Effect of argatroban (MD-805) on platelet function. Jpn Pharmacol Ther 14 (Suppl 5):13-19, 1986.
12. Nakamura K, Y Takano, K Mori: Thrombin-induced vasoconstriction in isolated cerebral arteries and the influence of a synthetic thrombin inhibitor. Thromb Res 40:715-720, 1985.
13. Matsuo H, T Uematsu, K Umemura, Y Takiguchi, Y Asai, Y Muranaka, M Nakashima: A simple and reproducible cerebral thrombosis model in rats induced by a photochemical reaction and the effect of a tissue plasminogen activator in this model. J Pharmacol Toxicol Methods 29:165-173, 1993.
14. Kawai Y, S Yuki, J Sugimoto, Y Tamao: Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 278:780-785, 1996.
15. Tanaka Y, S Kawabata, R Sin, K Takatuka, H Nisimura, N Yoshikawa, T Komatu: Therapeutic effect of argatroban (MD-805), antithrombin agent, in the acute stage of cerebral thrombosis. J Clin Ther Med 3:133-142, 1987.
16. Imiya M, T Matsuo: In vitro and in vivo inhibition of platelet aggregation by argatrohan (MD-805) in a patient with subacute cerebral thrombosis. Med Cons New Remed 29:991-916, 1992.